Journal of the National Comprehensive Cancer Network : JNCCN · 2024
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shah Neil P, Bhatia Ravi, Altman Jessica K, Amaya Maria, Begna Kebede H, Berman Ellin, Chan Onyee, Clements Joan, Collins Robert H, Curtin Peter T, DeAngelo Daniel J, Drazer Michael, Maness Lori, Metheny Leland, Mohan Sanjay, Moore Joseph O, Oehler Vivian, Pratz Keith, Pusic Iskra, Rose Michal G, Shomali William, Smith B Douglas, Styler Michael, Talpaz Moshe, Tanaka Tiffany N, Tantravahi Srinivas, Thompson James, Tsai Steven, Vaughn Jennifer, Welborn Jeanna, Yang David T, Sundar Hema, Gregory Kristina
Аннотация
Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome resulting from a reciprocal translocation between chromosomes 9 and 22 [t9;22] that gives rise to a BCR::ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase in developed countries. Tyrosine kinase inhibitor (TKI) therapy is a highly effective treatment option for patients with chronic phase-CML. The primary goal of TKI therapy in patients with chronic phase-CML is to prevent disease progression to accelerated phase-CML or blast phase-CML. Discontinuation of TKI therapy with careful monitoring is feasible in selected patients. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with chronic phase-CML.